SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s, Vivus settle long-pending patent litigation for Qsymia

01 Sep 2017 Evaluate

Dr. Reddy’s Laboratories and Nasdaq-listed Vivus Inc. have entered into settlement agreement to resolve a long-pending patent litigation related to weight management capsule Qsymia.

The settlement permits the Hyderabad-based drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances. In the event of an early launch, Vivus will receive a royalty on sales of the generic version of the drug.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.



Dr. Reddys Lab Share Price

1287.25 -6.00 (-0.46%)
11-May-2026 14:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1880.40
Dr. Reddys Lab 1287.25
Cipla 1308.00
Zydus Lifesciences 954.10
Lupin 2266.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×